Accelerating Medicines Partnership Schizophrenia (AMP SCZ): developing tools to enable early intervention in the psychosis high risk state.
作者信息
Brady Linda S, Larrauri Carlos A
机构信息
National Institute of Mental Health, Bethesda, MD, USA.
National Alliance on Mental Illness, Arlington, VA, USA.
出版信息
World Psychiatry. 2023 Feb;22(1):42-43. doi: 10.1002/wps.21038.
Abstract
摘要
相似文献
1
Accelerating Medicines Partnership Schizophrenia (AMP SCZ): developing tools to enable early intervention in the psychosis high risk state.加速药物合作精神分裂症项目（AMP SCZ）：开发工具以实现对精神病高危状态的早期干预。
World Psychiatry. 2023 Feb;22(1):42-43. doi: 10.1002/wps.21038.
2
Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum.探究精神分裂症基因组和外显子组负担在整个精神病谱中的独立和联合作用。
Epidemiol Psychiatr Sci. 2020 Nov 17;29:e182. doi: 10.1017/S2045796020000943.
3
Association between exposome score for schizophrenia and functioning in first-episode psychosis: results from the Athens first-episode psychosis research study.精神分裂症外显子组评分与首发精神病患者功能的相关性：来自雅典首发精神病研究的结果。
Psychol Med. 2023 Apr;53(6):2609-2618. doi: 10.1017/S0033291721004542. Epub 2021 Nov 18.
4
The serotonin transporter gene 5-HTTLPR polymorphism is associated with affective psychoses but not with schizophrenia: A large-scale study in the Russian population.血清素转运体基因5-HTTLPR多态性与情感性精神病相关，但与精神分裂症无关：俄罗斯人群的大规模研究。
J Affect Disord. 2017 Jan 15;208:604-609. doi: 10.1016/j.jad.2016.10.020. Epub 2016 Oct 26.
5
Social cognition and real-life functioning in patient samples with 22q11.2 deletion syndrome with or without psychosis, compared to a large sample of patients with schizophrenia only and healthy controls.与仅患有精神分裂症的大量患者样本和健康对照相比，伴有或不伴有精神病的22q11.2缺失综合征患者样本的社会认知和现实生活功能。
J Neuropsychol. 2023 Sep;17(3):564-583. doi: 10.1111/jnp.12322. Epub 2023 May 9.
6
Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia.甲基苯丙胺所致精神病与精神分裂症之间存在共享遗传风险的证据。
Neuropsychopharmacology. 2013 Sep;38(10):1864-70. doi: 10.1038/npp.2013.94. Epub 2013 Apr 12.
7
Reduced magnetic mismatch negativity: a shared deficit in psychosis and related risk.磁刺激错误相关负波减小：精神病及相关风险的共同缺陷。
Psychol Med. 2023 Oct;53(13):6037-6045. doi: 10.1017/S003329172200321X. Epub 2022 Nov 2.
8
Replication and cross-phenotype study based upon schizophrenia GWASs data in the Japanese population: support for association of MHC region with psychosis.基于日本人群精神分裂症 GWAS 数据的复制和跨表型研究：支持 MHC 区域与精神病的关联。
Am J Med Genet B Neuropsychiatr Genet. 2014 Jul;165B(5):421-7. doi: 10.1002/ajmg.b.32246. Epub 2014 May 29.
9
Elevated levels of IL-18 associated with schizophrenia and first episode psychosis: A systematic review and meta-analysis.白细胞介素-18 水平升高与精神分裂症和首发精神病有关：系统评价和荟萃分析。
Early Interv Psychiatry. 2021 Aug;15(4):896-905. doi: 10.1111/eip.13031. Epub 2020 Sep 9.
10
Face and emotion recognition in individuals diagnosed with schizophrenia, ultra-high risk for psychosis, unaffected siblings, and healthy controls in a sample from Turkey.来自土耳其的一个样本中，对被诊断为精神分裂症、精神病超高风险个体、未受影响的兄弟姐妹以及健康对照者进行面部和情绪识别。
Schizophr Res Cogn. 2024 Feb 3;36:100301. doi: 10.1016/j.scog.2024.100301. eCollection 2024 Jun.
引用本文的文献
1
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.加速药物合作精神分裂症项目参与者的基线临床特征
Schizophr Bull Open. 2025 Aug 25;6(1):sgaf012. doi: 10.1093/schizbullopen/sgaf012. eCollection 2025 Jan.
2
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.加速药物合作精神分裂症项目中的样本确定与招募来源
Schizophr Bull Open. 2025 Aug 25;6(1):sgaf013. doi: 10.1093/schizbullopen/sgaf013. eCollection 2025 Jan.
3
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.加速药物合作组织精神分裂症项目的脑电图方案：测量的可靠性与稳定性
Schizophrenia (Heidelb). 2025 Jun 6;11(1):85. doi: 10.1038/s41537-025-00622-0.
4
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的数字健康技术
Schizophrenia (Heidelb). 2025 Jun 3;11(1):83. doi: 10.1038/s41537-025-00599-w.
5
The evolving field of digital mental health: current evidence and implementation issues for smartphone apps, generative artificial intelligence, and virtual reality.数字心理健康的发展领域：智能手机应用程序、生成式人工智能和虚拟现实的当前证据及实施问题
World Psychiatry. 2025 Jun;24(2):156-174. doi: 10.1002/wps.21299.
6
Pathways to prevention: the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program.预防途径：加速药物合作组织精神分裂症（AMP® SCZ）项目
Schizophrenia (Heidelb). 2025 Apr 15;11(1):62. doi: 10.1038/s41537-025-00605-1.
7
Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program.架起科学与希望的桥梁：在加速药物合作组织精神分裂症项目中整合并传达生活经验
Schizophrenia (Heidelb). 2025 Apr 7;11(1):57. doi: 10.1038/s41537-025-00572-7.
8
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的样本确定与临床结局指标
Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7.
9
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的数据分析策略
Schizophrenia (Heidelb). 2025 Apr 3;11(1):53. doi: 10.1038/s41537-025-00561-w.
10
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.加速药物合作组织精神分裂症项目中的认知评估：不同国际样本中的协调重点与策略
Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1.
本文引用的文献
1
Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry.临床精神病高危范式中的预测与预防：现状综述及未来研究方向建议
Front Psychiatry. 2021 Oct 22;12:770774. doi: 10.3389/fpsyt.2021.770774. eCollection 2021.
2
Probability of Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis.临床高风险个体向精神病转化的概率：一项更新的荟萃分析。
JAMA Psychiatry. 2021 Sep 1;78(9):970-978. doi: 10.1001/jamapsychiatry.2021.0830.
3
Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis.精神病临床高危人群中阳性症状、阴性症状、功能及缓解的纵向转归：一项荟萃分析
EClinicalMedicine. 2021 Jun 16;36:100909. doi: 10.1016/j.eclinm.2021.100909. eCollection 2021 Jun.
4
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年 369 种疾病和伤害导致的全球负担：2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
5
Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population.预测精神病超高危人群的精神病后临床结局。
Early Interv Psychiatry. 2021 Jun;15(3):642-651. doi: 10.1111/eip.13002. Epub 2020 Jun 17.
6
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.预防精神病学：检测、预后和干预的新进展。
JAMA Psychiatry. 2020 Jul 1;77(7):755-765. doi: 10.1001/jamapsychiatry.2019.4779.
Zotero 插件